LEADER 01379oam  2200385   450 
001 9910703654703321
005 20150623164446.0
035   $a(CKB)5470000002433164
035   $a(OCoLC)905548008
035   $a(EXLCZ)995470000002433164
100   $a20150324g20159999  ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aImproving Regulatory Transparency for New Medical Therapies Act $ereport (to accompany H.R. 639)
210  1$a[Washington, D.C.] :$c[U.S. Government Publishing Office],$d[2015]-
215   $a1 online resource (volumes)
225 1 $aRept. / 114th Congress, 1st session, House of Representatives ;$v114-41
300   $aTitle from pt. 1 title screen (viewed on Mar. 24, 2015).
300   $a"March 16, 2015"--Pt. 1.
517   $aImproving Regulatory Transparency for New Medical Therapies Act 
606   $aDrugs of abuse$xLaw and legislation$zUnited States
606   $aDrug approval$zUnited States
608   $aLegislative materials.$2lcgft
615  0$aDrugs of abuse$xLaw and legislation
615  0$aDrug approval
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910703654703321
996   $aImproving Regulatory Transparency for New Medical Therapies Act$93216964
997   $aUNINA